Moderna shares surge 177% as cancer vaccine trial data draws renewed investor interest

The therapy being studied pairs Moderna's mRNA-based vaccine with Merck's Keytruda. mRNA vaccines work by delivering genetic instructions that teach the body's immune system to recognize and attack specific markers on tumor cells. The approach is being tested in patients with melanoma, a serious form of skin cancer, and represents one of the more advanced attempts to turn cancer into a treatable, immune-driven condition.

How the therapy works

Independent experts have framed the data as a milestone. Professor Ralf Gutzmer, director of the dermatology clinic at the university hospital in Minden, described the therapy as a breakthrough, saying: "Es ist die erste Impfung gegen Krebs, die in einer großen Phase-3-Studie nach modernsten Gesichtspunkten einen Effekt gezeigt hat." The endorsement from a senior clinician outside the companies involved has added weight to the bullish narrative around the stock, though the underlying Phase 3 results are still undergoing regulatory review.

Why investors are paying attention

Investors are also weighing the broader commercial picture. Moderna's revenue base remains heavily concentrated in COVID-19 vaccine sales, which have declined as the pandemic has faded. A successful oncology franchise would give it a second major pillar and reduce its dependence on a single product line. Analysts note that even modest uptake in melanoma could translate into several billion dollars in annual sales if the therapy is approved.

The stock move comes alongside an active news cycle for the project. Intismeran, the working name for the Moderna and Merck vaccine, has been discussed in investor presentations, medical conferences and media coverage throughout 2026, with patient enrollment in the confirmatory Phase 3 study continuing at multiple sites. Merck, the larger of the two partners, brings commercial reach and a deep oncology portfolio that includes Keytruda, while Moderna contributes the mRNA platform and manufacturing capacity.

What happens next

For now, the rally is being driven less by fresh clinical news and more by a reassessment of how the existing data could translate into future revenue. Traders point to options activity and short-covering as additional factors behind the sharp move, while longer-term investors are focused on whether the survival benefit seen in earlier studies will hold up in the larger confirmatory study. The companies have not yet announced a regulatory submission date.

Beyond melanoma, the partners are exploring additional tumor types in smaller trials, including lung and other skin cancers. If those early signals translate into Phase 3 benefit, the platform could eventually underpin a portfolio of personalized cancer vaccines tailored to individual patients' tumors. That longer-horizon ambition is part of why the latest dataset continues to draw attention, even though confirmatory trial readouts remain the decisive milestone for any approval.

Investors will be watching the next scheduled medical conference for further updates, as well as any commentary from regulators about the design of the confirmatory study. The 177 percent move, while dramatic, is a single trading session and does not by itself confirm a sustained recovery for the stock. What the rally does signal is that the market still views the cancer vaccine program as the central catalyst for Moderna's next chapter.